New cocktail of four drugs targets tough sarcomas in kids

NCT ID NCT07444619

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase trial tests a combination of four drugs—pazopanib, trabectedin, ipilimumab, and nivolumab—in children and young adults up to age 30 whose soft tissue sarcomas have come back. The goal is to see if adding pazopanib to the existing three-drug regimen is safe and helps control the cancer. Only 18 participants will be enrolled at M.D. Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pazopanib, trabectedin, ipilimumab, and nivolumab
What this could lead to: If successful, this could lead to a new combination therapy that helps control recurrent soft tissue sarcomas in young patients.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so safety and effectiveness are not yet known. The drug combination may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMAS

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.